KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Return on Capital Employed (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Return on Capital Employed readings, the most recent being 119.97% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 12074.0% to 119.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 119.97%, a 12074.0% increase, with the full-year FY2025 number at 111.35%, up 11209.0% from a year prior.
  • Return on Capital Employed hit 119.97% in Q4 2025 for Biocryst Pharmaceuticals, up from 29.09% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 119.97% in Q4 2025 to a low of 129.03% in Q3 2021.
  • Median Return on Capital Employed over the past 5 years was 27.25% (2023), compared with a mean of 25.59%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -3428bps in 2021 and later skyrocketed 12074bps in 2025.
  • Biocryst Pharmaceuticals' Return on Capital Employed stood at 54.98% in 2021, then surged by 40bps to 33.08% in 2022, then rose by 15bps to 28.03% in 2023, then soared by 97bps to 0.77% in 2024, then surged by 15690bps to 119.97% in 2025.
  • The last three reported values for Return on Capital Employed were 119.97% (Q4 2025), 29.09% (Q3 2025), and 18.6% (Q2 2025) per Business Quant data.